Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.

Valérie Delbos (1, 2) , Ludovic Lemée (1, 2) , Jacques Benichou (1, 3) , Gilles Berthelot (4) , Ala-Eddine Deghmane (5) , Jean-Philippe Leroy (1) , Estelle Houivet (1) , Eva Hong (5) , Muhamed-Kheir Taha (5) , François Caron (1, 2)

1 CHU Rouen
2 UNIROUEN - Université de Rouen Normandie
3 INSERM - Institut National de la Santé et de la Recherche Médicale
4 Centre hospitalier de Dieppe
5 Institut Pasteur [Paris]

The aim of the study was to analyze the impact of MenBvac, an outer membrane vesicle (OMV) vaccine against P1.7,16 strains, on meningococcal carriage. During a B:14:P1.7,16/ST-32 outbreak in Normandy (France), children aged 1-7 years were randomly selected to participate in the study. Among the 1082 volunteers, there were 17 Neisseria meningitidis carriers (carriage rate of 1.57%). MenBvac vaccination appeared associated with lower carriage rate, i.e., 0.31% among the vaccinated children versus 2.10% among the non-vaccinated (p=0.03). The beneficial effect on carriage was observed regardless of the strain serogroup. OMV-vaccinated mice also showed reduction of bacterial acquisition of OMV-homolog and hererolog strains in respiratory pathways after intranasal challenge. These results suggest that meningococcal OMV-based vaccines reduce meningococcal carriage and may hence confer herd immunity.

Keywords: Carriage; Meningococci; Outbreak; Outer membrane vesicle vaccine

Domains: Life Sciences [q-bio]; Immunology; Vaccinology

Valérie Delbos, Ludovic Lemée, Jacques Benichou, Gilles Berthelot, Ala-Eddine Deghmane, et al.. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.. Vaccine, 2013, 31 (40), pp.4416-4420. ⟨10.1016/j.vaccine.2013.06.080⟩. ⟨pasteur-02073842⟩